| Study       | DL incidence (%) | 95% CI       |
|-------------|------------------|--------------|
| Study 1     | 0.77%            | 0.72, 10.71  |
| Study 2     | 0.28%            | 0.01, 1.89   |
| Study 3     | 0.96%            | 0.81, 7.46   |
| Study 4     | 0.78%            | 0.60, 2.35   |
| Study 5     | 0.48%            | 0.07, 3.27   |
| Study 6     | 0.28%            | 0.03, 6.84   |
| Study 7     | 1.35%            | 0.49, 3.44   |
| Study 8     | 0.28%            | 0.03, 4.19   |
| Study 9     | 0.28%            | 0.03, 7.42   |
| Study 10    | 0.28%            | 0.02, 4.19   |
| Study 11    | 0.48%            | 0.07, 3.27   |
| Study 12    | 0.28%            | 0.03, 7.21   |
| Study 13    | 0.96%            | 0.81, 7.46   |
| Study 14    | 0.28%            | 0.03, 6.84   |
| Study 15    | 1.35%            | 0.49, 3.44   |
| Study 16    | 0.28%            | 0.03, 4.19   |
| Study 17    | 0.28%            | 0.03, 7.42   |
| Study 18    | 0.28%            | 0.03, 4.19   |

**POPF related POMR (group A1−B1)**

**POPF related POMR (group A2−B2)**

**POPF related POMR (group C)**